Literature DB >> 17021605

Cellular focal segmental glomerulosclerosis: Clinical and pathologic features.

M B Stokes1, A M Valeri, G S Markowitz, V D D'Agati.   

Abstract

Five pathologic variants of idiopathic focal segmental glomerulosclerosis (FSGS) are recognized: collapsing (COLL), cellular (CELL), glomerular tip lesion (GTL), perihilar, and not otherwise specified (NOS). The prognostic significance of CELL FSGS has not been determined. We compared the presenting clinical and pathologic characteristics in 225 patients with CELL (N=22), COLL (N=56), GTL (N=60), and NOS (N=87) variants of idiopathic FSGS. CELL, COLL, and tip lesion all showed greater frequency and severity of nephrotic syndrome, and shorter time to biopsy compared to NOS. Predictors of end-stage renal disease (ESRD) for all FSGS patients included initial serum creatinine, % global sclerosis, % COLL lesions, chronic tubulo-interstitial injury score, and lack of remission response. COLL FSGS had the highest rate of renal insufficiency at presentation, most extensive glomerular involvement and chronic tubulo-interstitial disease, fewest remissions (13.2%), and highest rate of ESRD (65.3%). GTL patients were older and showed the highest remission rate (75.8%) and lowest rate of ESRD (5.7%). CELL variant showed intermediate rates of remission (44.5%) and ESRD (27.8%) compared to COLL and tip lesion. CELL variant may include cases of unsampled tip or COLL lesion, underscoring the importance of adequate sampling. Our data support the view that CELL and COLL FSGS are not equivalent and validates an approach to pathologic classification that distinguishes between COLL, CELL, and tip lesion variants of FSGS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021605     DOI: 10.1038/sj.ki.5001903

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  49 in total

Review 1.  Glomerular diseases: FSGS.

Authors:  Bhadran Bose; Daniel Cattran
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

2.  Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.

Authors:  Louis-Philippe Laurin; Adil M Gasim; Caroline J Poulton; Susan L Hogan; J Charles Jennette; Ronald J Falk; Bethany J Foster; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-16       Impact factor: 8.237

3.  Fidelity and evolution of recurrent FSGS in renal allografts.

Authors:  Daphne H T IJpelaar; Alton B Farris; Natascha Goemaere; Kerstin Amann; Roel Goldschmeding; Tri Q Nguyen; Evan Farkash; Marius C van den Heuvel; Emile de Heer; Jan A Bruijn; Robert B Colvin; Ingeborg M Bajema
Journal:  J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 10.121

Review 4.  Foam cells and the pathogenesis of kidney disease.

Authors:  Minseob Eom; Kelly L Hudkins; Charles E Alpers
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

5.  Complex glomerular pathology of thrombotic microangiopathy and focal segmental glomerulosclerosis forms tumor-like mass in a renal transplant donor with severe renovascular hypertension.

Authors:  Michio Nagata; Yutaka Yamaguchi; Daisuke Toki; Izumi Yamamoto; Hiroaki Shinmura; Hiroshi Kawaguchi
Journal:  CEN Case Rep       Date:  2016-09-26

6.  A case of the "cellular variant" of focal segmental glomerulosclerosis with acute renal failure that remitted completely with oral steroid administration.

Authors:  Gaku Konno; Go Someya; Kazuma Sekine; Takuya Nishino; Shinya Kawamoto
Journal:  CEN Case Rep       Date:  2012-06-19

7.  Association of histologic variants in FSGS clinical trial with presenting features and outcomes.

Authors:  Vivette D D'Agati; Joan M Alster; J Charles Jennette; David B Thomas; James Pullman; Daniel A Savino; Arthur H Cohen; Debbie S Gipson; Jennifer J Gassman; Milena K Radeva; Marva M Moxey-Mims; Aaron L Friedman; Frederick J Kaskel; Howard Trachtman; Charles E Alpers; Agnes B Fogo; Tom H Greene; Cynthia C Nast
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

8.  Collapsing Glomerulopathy: A Single Centre Clinicopathologic Study of Seven Years.

Authors:  Kamal V Kanodia; Aruna V Vanikar; Rashmi D Patel; Kamlesh S Suthar; Lovelesh K Nigam; Himanshu V Patel; Vivek Kute; Hargovind L Trivedi
Journal:  J Clin Diagn Res       Date:  2016-04-01

9.  Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss.

Authors:  Toshiharu Ueno; Namiko Kobayashi; Makiko Nakayama; Yasutoshi Takashima; Takamoto Ohse; Ira Pastan; Jeffrey W Pippin; Stuart J Shankland; Noriko Uesugi; Taiji Matsusaka; Michio Nagata
Journal:  Kidney Int       Date:  2013-02-27       Impact factor: 10.612

10.  Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.

Authors:  Louis-Philippe Laurin; Adil M Gasim; Vimal K Derebail; JulieAnne G McGregor; Jason M Kidd; Susan L Hogan; Caroline J Poulton; Randal K Detwiler; J Charles Jennette; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-21       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.